Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review
Chao‐Yie Yang, Chong Qin, Longchuan Bai, et al.
Drug Discovery Today Technologies (2019) Vol. 31, pp. 43-51
Closed Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem, Craig M. Crews
Cell (2020) Vol. 181, Iss. 1, pp. 102-114
Open Access | Times Cited: 776
PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 513
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
Daiki Takahashi, Jun Moriyama, Tomoe Y. Nakamura, et al.
Molecular Cell (2019) Vol. 76, Iss. 5, pp. 797-810.e10
Open Access | Times Cited: 444
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova, William D. Foulkes, Michael Witcher
British Journal of Cancer (2021) Vol. 124, Iss. 9, pp. 1478-1490
Open Access | Times Cited: 280
PHOTACs enable optical control of protein degradation
Martin Reynders, Bryan S. Matsuura, Marleen Bérouti, et al.
Science Advances (2020) Vol. 6, Iss. 8
Open Access | Times Cited: 226
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
Shipeng He, Fei Gao, Junhui Ma, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 43, pp. 23299-23305
Closed Access | Times Cited: 192
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Shanique Alabi, Craig M. Crews
Journal of Biological Chemistry (2021) Vol. 296, pp. 100647-100647
Open Access | Times Cited: 189
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow, Pragya Adhikari, Robert A. Blake, et al.
ChemMedChem (2019) Vol. 15, Iss. 1, pp. 17-25
Closed Access | Times Cited: 150
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Pan Tang, Jifa Zhang, Jie Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2419-2435
Open Access | Times Cited: 109
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
Matthew R. Burke, Alexis R. Smith, Guangrong Zheng
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 69
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 24
BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs
Patrícia Cristine Borck, Lian‐Wang Guo, Jorge Plutzky
Circulation Research (2020) Vol. 126, Iss. 9, pp. 1190-1208
Open Access | Times Cited: 121
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Valerie J. Carpenter, Tareq Saleh, David A. Gewirtz
Cancers (2021) Vol. 13, Iss. 4, pp. 723-723
Open Access | Times Cited: 90
Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Jaeki Min, Anand Mayasundari, Fatemeh Keramatnia, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 51, pp. 26663-26670
Open Access | Times Cited: 89
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
Junping Pei, Guan Wang, Lu Feng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 3493-3507
Closed Access | Times Cited: 85
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
José Luis Morgado‐Pascual, Sandra Rayego‐Mateos, Lucía Tejedor-Santamaria, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 83
Targeted degradation via direct 26S proteasome recruitment
Charlene Bashore, Sumit Prakash, Matthew C. Johnson, et al.
Nature Chemical Biology (2022) Vol. 19, Iss. 1, pp. 55-63
Open Access | Times Cited: 67
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 63
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 47
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 44
Phenyl Dihydrouracil: An Alternative Cereblon Binder for PROTAC Design
Jamie Jarusiewicz, Satoshi Yoshimura, Anand Mayasundari, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 2, pp. 141-145
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top